Navigation Links
VG Life Sciences, Inc. Announces Management Changes

SANTA BARBARA, Calif., July 18, 2013 /PRNewswire/ -- VG Life Sciences, (OTC Pink: VGLS) a biotechnology company, announces alterations in its corporate management and management structure.

Interim CEO & President

John Tynan has been named Interim CEO & President of VG Life Sciences, inc, effective immediately. Mr. Tynan started TynanGroup, Inc. in 1991 and grew it to successful company as a leader in real estate development services across the country, overseeing more than $4 billion of construction. TynanGroup was on INC Magazine's list of the fasting growing companies and today includes a host of sister companies including MedBridge Development Company, LLC and Anchor Point IT Solutions. Prior to starting TynanGroup, he was Vice President for Hyatt Development Corporation where he oversaw $1.5 Billion project expenditures and over 9,000 people. Mr. Tynan has a BS in Civil Engineering from the University of Illinois and a MBA in finance from DePaul University. "My focus is on achieving specific goals to increase shareholders' value and support our exceptional research team," said Tynan. Haig Keledjian will stay on as Chairman of the Board and VP of Intellectual Property and Product Development.

For more information on the goals and direction of the company as well as the new management structure of VG Life Sciences, please see the July 18th, 2013 investor letter, which can be downloaded from the company site and viewed here.

About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious diseases, and autoimmune disorders.  VGLS controls over 50 US and international patents and pending patents protecting its exclusive biotech platform technologies. For more information, visit

Alexandria Sumner, Corporate Communications
VG Life Sciences, Inc.
Phone:  (805) 679-6763

SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
2. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
3. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
4. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
5. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
6. Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference
7. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
8. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
9. Jaipal Reddy, Honble Minister of Science and Technology & Earth Sciences, Inaugurates the International Bioenergy Summit in Delhi
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... BC (PRWEB) , ... November 24, 2015 , ... ... our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast ... Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that ...
(Date:11/24/2015)... HemoShear Therapeutics, LLC, a privately held ... disorders, announced today the appointment of H. ... (BOD). Mr. Watkins is the former president and ... and also served as the chairman of the ... Chairman and CEO of HemoShear Therapeutics. "The combination ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
Breaking Biology Technology:
(Date:11/19/2015)... -- Although some 350 companies are actively involved in molecular ... according to Kalorama Information. These include Roche Diagnostics, Hologic, Abbott ... of the 6.1 billion-dollar molecular testing market, according to ... Diagnostic s .    ... one company and only a handful of companies can ...
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):